Clinical relevance of comorbidity in anxiety disorders: A report from the Netherlands Study of Depression and Anxiety (NESDA)

Mieke Klein Hofmeijer-Sevink a,b,⁎, Neeltje M. Batelaan a, Harold J.G.M. van Megen b, Brenda W. Penninx a,c,d, Danielle C. Cath e,f, Marcel A. van den Hou e,f, Anton J.L.M. van Balkom a

a Department of Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands
b Mental Health Care Institute GGZ Central, Ermelo, The Netherlands
c Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands
d Department of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands
e Department of Clinical and Health Psychology, Utrecht University, The Netherlands
f Academic Anxiety Center, GGZ Altrecht, Utrecht, The Netherlands

Article info

Article history:
Received 4 July 2011
Received in revised form 8 December 2011
Accepted 8 December 2011
Available online 10 January 2012

Keywords:
Anxiety
Depression
Comorbidity

Abstract

Background: To study the clinical relevance of type of comorbidity and number of comorbid disorders in anxiety disorders. Four groups were compared according to sociodemographic-, vulnerability- and clinical factors: single anxiety disorder, anxiety–anxiety comorbidity, anxiety–depressive comorbidity and “double” comorbidity (i.e. anxiety and depressive comorbidity).

Methods: Data were obtained from the Netherlands Study of Anxiety and Depression (NESDA). A sample of 1004 participants with a current anxiety disorder was evaluated.

Results: As compared with single anxiety, anxiety–anxiety comorbidity was associated with higher severity, greater chronicity and more treatment. Anxiety–anxiety comorbidity was associated with an earlier age of onset and a more chronic course compared with anxiety–depressive comorbidity, while anxiety–depressive comorbidity was associated with more severe symptoms and more impaired functioning than anxiety–anxiety comorbidity. “Double” comorbidity was associated with higher severity, greater chronicity, more treatment and increased disability. Sociodemographic and vulnerability factors were comparable among the four groups.

Limitations
A prospective design would be more appropriate to study the outcome. In this study no distinction was made between whether depression or anxiety disorder preceded the current anxiety disorder.

Conclusions: It is clinical relevant to diagnose and treat comorbidity among anxiety disorders as it is associated with higher severity and more chronicity. Whereas anxiety–anxiety comorbidity has an earlier age of onset and a more chronic course, anxiety–depressive comorbidity leads to more treatment and impaired functioning. “Double” comorbidity leads to even more severity, chronicity and impairment functioning compared with both anxiety–anxiety and anxiety–depressive comorbidity.

© 2011 Elsevier B.V. Open access under the Elsevier OA license.

1. Introduction

Comorbidity in anxiety disorders represents the rule rather than the exception. Lifetime comorbidity in patients with anxiety disorders occurs in more than 80% (Brown et al., 2001). The prevalence of having a current comorbid axis I disorder is

⁎ Corresponding author at: GGZ Centraal, lokatie Veldwijk, Afdeling Johannesbos, Postbus 1000, 3853 BA, Ermelo, The Netherlands. Tel.: +31 341 566 911, +31 613 576 620 (M); fax: +31 341 566 686.
E-mail addresses: m.klein2@ggzcentraal.nl, m.kleinhofmeijer@ggzingeest.nl (M. Klein Hofmeijer-Sevink).

0165-0327 © 2011 Elsevier B.V. Open access under the Elsevier OA license.
Comorbidity between anxiety disorders and depressive disorders has been widely investigated. Anxiety–depressive comorbidity has been associated with sociodemographic factors such as female gender, not having a partner, lower socio-economic status and lower educational level (Alonso et al., 2004; de Graaf et al., 2002; Fichter et al., 2010); with vulnerability factors such as parental psychiatric history, childhood trauma, negative life events and neuroticism (de Graaf et al., 2002); and with clinical factors including younger age of onset (Fichter et al., 2010), illness severity, poorer outcome (Angst and Vollrath, 1991; Merikangas et al., 2003; Rush et al., 2005), higher healthcare utilization (Kessler et al., 1994) and impaired functioning (Fichter et al., 2010; Kessler and Frank, 1997).

Although anxiety–anxiety comorbidity occurs as frequently as anxiety–depressive comorbidity, it has received surprisingly little attention to-date. Fragmentized research suggests that, compared with single anxiety disorders, patients with anxiety–anxiety comorbidity suffer from more severe anxiety symptoms (van Balkom et al., 2008). In addition, anxiety–anxiety comorbidity may be associated with lower levels of extraversion and higher levels of neuroticism (Chambers et al., 2004). Finally, individuals with anxiety–anxiety comorbidity more frequently report a history of childhood abuse (Cougle et al., 2010). However, anxiety–anxiety comorbidity may not be associated with lower levels of functioning compared with single anxiety disorders (Barrera and Norton, 2009; Grant et al., 2005; Norberg et al., 2008).

Given the lack of data regarding anxiety–anxiety comorbidity, further research is needed. It is important to determine whether it is clinically relevant to diagnose type of comorbidity and number of comorbid disorders in anxiety disorders so as to be able to identify patients at a high risk for developing a comorbid disorder and to direct treatment at the disorders present.

1.1. Aims of the study

Using data from the Netherlands Study of Anxiety and Depression (NESDA), the clinical relevance of (i) type of comorbidity and (ii) number of comorbid disorders in a clinical sample suffering from anxiety disorders was studied. Four groups were compared: single anxiety disorder, anxiety–anxiety comorbidity, anxiety–depressive comorbidity and “double” comorbidity (i.e. anxiety and depressive comorbidity). We investigated sociodemographics, vulnerability factors and clinical characteristics to determine whether:

1) anxiety–anxiety comorbidity differs from a single anxiety disorder
2) anxiety–anxiety comorbidity differs from anxiety–depressive comorbidity (type of comorbidity)
3) “double” comorbidity differs from anxiety–anxiety comorbidity and from anxiety–depressive comorbidity (number of comorbid disorders).
Vulnerability factors included a family history of anxiety and depressive disorders, childhood trauma, negative life events and personality traits. A first-degree family history of anxiety and depressive disorders was assessed using the family tree method (Fyer and Weissman, 1999). Childhood trauma was assessed using the second section of the Childhood Trauma Interview previously used in the Netherlands Mental Health Survey and Incidence Study (NEMESIS, de Graaf et al., 2002). Childhood trauma was considered present in cases when participants experienced emotional neglect, psychological abuse or physical abuse on two or more occasions prior to age 16, or sexual abuse on one or more occasions prior to age 16. Negative life events in the past year were measured with the List of Threatening Experiences (Brugha et al., 1985). This list has good reliability and good validity (Brugha and Cragg, 1990). Finally, personality traits were measured with the 60-item NEO-FFI personality questionnaire, which uses 5 dimensions for personality: neuroticism, extraversion, openness, agreeableness and conscientiousness (Costa and McCrae, 1995). This scale has proven to be reliable and valid (Costa and McCrae, 1992).

Clinical characteristics included age of onset (in years), chronicity of symptoms (yes/no), severity of depressive, anxiety and avoidance symptoms (assessed as a continuous variable), treatment (yes/no) and disability (assessed as a continuous variable). Age of onset was determined with the CIDI, and the youngest age of onset was used in the case of comorbidity. The chronicity of symptoms was based on the Life Chart Interview (Lyketsos et al., 1994) in which the presence of anxiety and/or depressive symptoms was retrospectively assessed for the preceding 4 years. Symptoms were defined as chronic when they occurred during more than 50% of the months during the preceding 4 years. The Life Chart Interview has shown high validity and reliability (Warshaw et al., 1994). Receiving treatment was defined as having received antidepressant medication and/or psychotherapy. The use of antidepressant medication was determined on the basis of drug container inspection for all drugs used in the month before assessment. Use of antidepressants was considered positive when regular (defined as more than 50% of the time/daily for at least 1 month); these included TCAs, SSRIs and SNRIs. Psychotherapy was defined as more than 5 contacts with a therapist during the past 6 months. A therapist could be a psychologist, psychiatrist, psychotherapist, social worker or social psychiatric nurse working in general health care or in specialized mental health care. The frequency of contacts with a therapist was assessed using the Tic-P (Hakkaart-van Roijen, 2002). This is a validated instrument assessing loss of productivity at work and health care utilization. The severity of anxiety symptoms was assessed with the Beck Anxiety Inventory (BAI, Beck et al., 1988). The BAI is a 21-item self-report list. It is widely used and has proven to be highly valid and reliable (Fydrich et al., 1992). The level of avoidance was measured with the Fear Questionnaire (FQ, Marks and Matthews, 1979), a 15-item self-report list measuring phobic symptoms that has been proven valid in a Dutch population (van Zuuren, 1988). To determine the severity of depressive symptoms the Inventory of Depressive Symptomatology (IDS, Rush et al., 1996) was used. This scale is a 30-item self-report list measuring depressive symptoms that has proven to be valid and reliable (Trivedi et al., 2004). Negative consequences in three domains (cognitive, physical and social disability) were measured with The World Health Organization Disability Assessment Schedule (WHODAS II). This is a 36-item instrument that examines disability in six domains of life during the past 30 days and has proven to be valid and reliable (Chwastiak and Von Kurff, 2003).

2.5. Statistical analyses

All statistical analyses were conducted with the SPSS statistical package version 15.0. As described above, the sample was divided into four mutually exclusive categories: participants with a single anxiety disorder, with anxiety-anxiety comorbidity, with anxiety–depressive comorbidity and with “double” comorbidity. Bivariate multinomial logistic regression analyses were conducted to examine the clinical factors of comorbidity. Dependent on the research question, different groups were taken as the reference group. Subsequently, risk-indicators (sociodemographics and vulnerability factors) were examined. Both bivariate and multivariate multinomial logistic regression analyses were conducted. In the multivariate model, we adjusted for all covariates that were significant in the bivariate analyses.

3. Results

3.1. Characteristics of the sample

The sociodemographics and clinical characteristics of the sample are presented in Table 1. The sample was predominantly female (72.1%). The mean age of onset was 20.9 years (SD: 12.3). Forty-five percent of the sample suffered from chronic symptoms and about half of the sample had received treatment (51.3%).

3.2. Anxiety–anxiety comorbidity

To investigate whether anxiety–anxiety comorbidity is associated with various clinical factors and various risk indicators compared with single anxiety disorders, participants

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Socio-demographic- and clinical characteristics of the sample (n = 1004).</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>(n)</td>
</tr>
<tr>
<td>Female gender</td>
<td>72.1 (724)</td>
</tr>
<tr>
<td>Partner</td>
<td>66.7 (670)</td>
</tr>
<tr>
<td>Chronicity</td>
<td>45.3 (455)</td>
</tr>
<tr>
<td>Treatment</td>
<td>51.3 (515)</td>
</tr>
<tr>
<td>Mean Age (years)</td>
<td>41.0 (12.6)</td>
</tr>
<tr>
<td>Education (years)</td>
<td>11.7 (3.2)</td>
</tr>
<tr>
<td>Age of onset (years)</td>
<td>20.9 (12.3)</td>
</tr>
<tr>
<td>Total IDS score</td>
<td>28.3 (12.6)</td>
</tr>
<tr>
<td>Total BAI score</td>
<td>17.7 (10.7)</td>
</tr>
<tr>
<td>Total FQ score</td>
<td>34.7 (20.1)</td>
</tr>
<tr>
<td>Cognitive disability</td>
<td>31.5 (20.9)</td>
</tr>
<tr>
<td>Physical disability</td>
<td>18.7 (21.7)</td>
</tr>
<tr>
<td>Social disability</td>
<td>32.8 (20.6)</td>
</tr>
</tbody>
</table>

IDS = Inventory of Depressive Symptomatology, BAI = Beck Anxiety Inventory, FQ = Fear Questionnaire.
with a single anxiety disorder (n = 295) were compared with those with anxiety–anxiety comorbidity (n = 105). The results are presented in Tables 2 and 3.

Participants with anxiety–anxiety comorbidity had an earlier age of onset than those with a single anxiety disorder (19.3 versus 23.0 years; OR: 0.73; 95% CI: 0.58–0.93) and a higher rate of chronicity (53.3% versus 32.2%; OR: 2.41; 95% CI: 1.53–3.79). Participants with anxiety–anxiety comorbidity experienced more severe depressive (OR: 1.52; 95% CI: 1.14–2.03), anxiety (OR: 1.58; 95% CI: 1.20–2.07) and avoidance symptoms (OR: 1.42; 95% CI: 1.10–1.82) than those with a single anxiety disorder. They experienced more social disability compared with participants with a single anxiety disorder (OR: 1.45; 95% CI: 1.16–1.98), but similar rates of cognitive and physical disability. Participants with anxiety–anxiety comorbidity did not receive significantly more treatment (40.0% versus 30.8%; OR: 1.50; 95% CI: 0.94–2.37).

Unadjusted bivariate analyses show that participants with anxiety–anxiety comorbidity more often had a positive family history of anxiety or depressive disorders (63.8% versus 45.9%; OR: 0.48; 95% CI: 0.30–0.76) had a positive family history for anxiety or depressive disorder. Those with anxiety–anxiety comorbidity had higher neuroticism levels (OR: 1.51; 95% CI: 1.16–1.98) and a higher rate of chronic anxiety or depressive comorbidity (OR: 2.07; 95% CI: 1.30–3.30) and the elevated neuroticism levels (OR: 1.98) remained significant, whereas the lower levels of extraversion were no longer significant (OR: 0.83; 95% CI: 0.64–1.08).

### 3.3. Type of comorbidity

To investigate whether anxiety–anxiety comorbidity is different from anxiety-depressive comorbidity with regard to all of the aspects mentioned above, participants with anxiety–anxiety comorbidity (n = 105) were compared with participants with anxiety-depressive comorbidity (n = 292).

Participants with anxiety–anxiety comorbidity had an earlier age of onset than those with anxiety-depressive comorbidity (19.3 years versus 22.6 years; OR: 1.33; 95% CI: 1.05–1.68) and a higher rate of chronic anxiety or depressive symptoms (53.3% versus 41.4%; OR: 0.62; CI: 0.40–0.99). The severity of anxiety and avoidance symptoms did not significantly differ between the groups. The depressive symptoms were however more severe among those with anxiety-depressive comorbidity (OR: 2.09; 95% CI: 1.58–2.77). Those with anxiety-depressive comorbidity had received significantly more treatment (55.1% versus 40.0%; OR: 1.84; 95% CI: 1.17–2.90) and they also experienced more cognitive (OR: 1.88; 95% CI: 1.44–2.46), physical (OR: 1.34; 95% CI: 1.02–1.76) and social disability (OR: 1.46; 95% CI: 1.13–1.89).

Like the unadjusted analyses, adjusted analyses show that participants with anxiety–anxiety comorbidity more often had a positive family history for anxiety or depressive disorders (63.8% versus 45.9%; OR: 0.48; 95% CI: 0.30–0.76) and elevated conscientiousness scores (OR: 0.77; 95% CI: 0.59–0.77).
3.4. Number of comorbid disorders

To investigate whether “double” comorbidity may be distinguished from anxiety–depressive comorbidity and anxiety–anxiety comorbidity, clinical factors and risk-indicators were compared. Both anxiety–anxiety comorbidity (n = 105) and anxiety–depressive comorbidity (n = 292) were compared with the group with double comorbidity (n = 312). The differences found are presented in Tables 2 and 3.

Compared with anxiety–anxiety comorbidity, “double” comorbidity was associated with more severe depressive (OR: 4.52; 95%CI: 3.35–6.10), anxiety (OR: 2.15; 95%CI: 1.66–2.78) and avoidance symptoms (OR: 1.80; 95%CI: 1.42–2.29). Participants with “double” comorbidity also received more treatment (70.8% versus 40.4%; OR: 3.64; 95%CI: 2.30–5.77) and experienced more disability in all domains compared with anxiety–anxiety comorbidity.

Compared with anxiety–depressive comorbidity, “double” comorbidity was associated with an earlier age of onset (18.0 versus 22.6 years; OR: 0.66; 95%CI: 0.59–0.77) and a higher rate of chronicity (58.7% versus 41.4%; OR: 2.01; 95%CI: 1.45–2.77). Those with “double” comorbidity experienced more severe depressive (OR: 2.16; 95%CI: 1.78–2.63), anxiety (OR: 1.97; 95%CI: 1.65–2.35) and avoidance symptoms (OR: 2.01; 95%CI: 1.68–2.39). They also received more treatment compared with those with anxiety–depressive comorbidity (70.8% versus 55.1%; OR: 1.98; 95%CI: 1.41–2.77) and experienced more disability in all domains.

The unadjusted bivariate models show that, compared with those with anxiety–anxiety comorbidity, participants with “double” comorbidity were less educated (10.9 versus 12.3 years) and were less likely to have a positive family history of anxiety or depressive disorders (52.6% versus 63.8%). They were more likely to have experienced childhood trauma (59.3% versus 40.4%) and negative life events in the past year (0.8 versus 0.5 negative life events). Those with “double” comorbidity had elevated neuroticism and conscientiousness levels and lower extraversion, openness and agreeableness levels. (Unadjusted statistics are not shown in the Table). After adjustment for all significant covariates in the bivariate model, the lower level of education (OR: 0.91; 95%CI: 0.84–0.98), higher neuroticism levels (OR: 1.86; 95%CI: 1.38–2.49) and lower extraversion scores (OR: 0.67; 95%CI: 0.51–0.88) remained significantly different between those with “double” comorbidity and those with anxiety–anxiety comorbidity.

Comparing participants with “double” comorbidity with those with anxiety–depressive comorbidity, unadjusted models show that those with “double” comorbidity were less educated (10.9 versus 11.8 years) and more likely to have experienced childhood trauma (59.3% versus 51.0%). They had elevated neuroticism levels and lower extraversion and openness levels. After adjustment for all significant covariates in the bivariate model, the lower level of education remained significantly different between those with “double” comorbidity and those with anxiety–depressive comorbidity (OR: 0.78; 95%CI: 0.65–0.93), as did the elevated neuroticism

OR 95% CI: confidence interval for covariates. P < 0.05 indicates bold data. OR per SD increase using multilevel logistic regression analyses.
levels (OR: 1.60; 95%CI: 1.30–1.97) and decreased extraversion levels (OR: 0.79; 95%CI: 0.58–0.85).

4. Discussion

4.1. Clinical characteristics of comorbidity

In a well-defined subsample of the NESDA study of 1004 participants with at least one anxiety disorder, the clinical relevance of comorbidity was studied. We may conclude that both the type of comorbidity and the number of comorbid disorders are clinically important to diagnose.

Anxiety–anxiety comorbidity was associated with more severe clinical characteristics compared with a single anxiety disorder. Patients with anxiety–anxiety comorbidity experienced more severe symptoms, more chronic symptoms and more social impairment. It should be noted that in anxiety–anxiety co-morbidity, not only anxiety symptoms were more severe, depressive symptoms were also more severe. These findings confirm an earlier finding of an association between anxiety–anxiety comorbidity and severity of symptoms (Cougle et al., 2010). The finding that anxiety–anxiety comorbidity is associated with more social impairment contradicts earlier research that could not find an association between the number of anxiety disorders and the quality of life (Barrera and Norton, 2009; Grant et al., 2005; Norberg et al., 2008).

Anxiety–anxiety comorbidity was associated with critically different clinical factors compared with anxiety–depression comorbidity: The course of anxiety–anxiety comorbidity was worse than the course of anxiety–depressive comorbidity, with an earlier age of onset and more chronicity. Anxiety–depressive comorbidity, however, is associated with more treatment and higher levels of disability. These results suggest that the type of comorbidity is important to diagnose, because it differentiates anxiety–anxiety comorbidity from anxiety–depressive comorbidity: the first type is more chronic, the second type is more invalidating. “Double” comorbidity in anxiety disorders appeared to lead to more severe symptoms, more treatment and more day-to-day impairment compared with anxiety–anxiety comorbidity or anxiety–depressive comorbidity. This indicates that the number of diagnoses present is related to severity, use of health care and negative consequences.

4.2. Sociodemographics and vulnerability factors of comorbidity

After adjusting for covariates, this study found that neuroticism is the most consistent risk-indicator associated with comorbidity in anxiety disorders. Neuroticism was lowest in patients with a single anxiety disorder, higher in patients with anxiety–anxiety comorbidity and anxiety–depressive comorbidity and highest in those with double comorbidity. This finding may not be specific for anxiety disorders but may reflect general vulnerability given that more psychiatric disorders are associated with high neuroticism (Cox et al., 2004; Enns and Cox, 1997; van Os and Jones, 2001). Ormel et al. (2004) argue that the association of neuroticism and psychopathology is tautological, since neuroticism reflects the presence of subthreshold anxiety and depressed feelings over a period of time, which obviously predict the development of an anxiety or depressive disorder.

4.3. Limitations and strengths

Several strengths and limitations should be taken into account. Strengths include the large sample size, the well-implemented design of the NESDA study and the use of the CIDI as a diagnostic instrument safeguarding statistical power and the reliability of results. Limitations include the cross-sectional design. A prospective design would be more appropriate to study the outcome. Another potential limitation of this study is Post Traumatic Stress Disorder, Obsessive–Compulsive Disorder and Specific Phobia were not assessed in the NESDA study. Moreover, the single anxiety disorders that were assessed were collapsed into one group to achieve sufficient statistical power. If these disorders had had different sociodemographics, vulnerability factors or clinical characteristics, analyzing anxiety disorders as one group could have resulted in a bias. Therefore, we have compared the specific anxiety disorders with each other (data not shown). All anxiety disorders appeared to be similar. Based on this, we feel it is justified to examine anxiety disorders as one group. Finally, in this study no distinction was made between whether depression or anxiety disorder preceded the current anxiety disorder, thus hampering establishment of whether or not comorbid depression might be secondary to the anxiety disorder. However, a recent study (Lamers et al., 2011) found no differences in clinical characteristics between comorbidity with preceding depression and comorbidity with preceding anxiety.

5. Conclusion

This study adds to current knowledge on comorbidity in anxiety disorders. Its results clearly showed that it is important to diagnose comorbidity among anxiety disorders as it is associated with higher severity and more chronicity compared with single anxiety disorders. In addition, it is also important to distinguish the type and number of comorbid disorders: Whereas anxiety–anxiety comorbidity has an earlier age of onset and a more chronic course, anxiety–depressive comorbidity leads to more treatment and impaired functioning. Furthermore, “double” comorbidity leads to even more severity, chronicity and impairment compared with both anxiety–anxiety and anxiety–depressive comorbidity. These findings indicate that in clinical practice all comorbid disorders present in patients with an anxiety disorder should be diagnosed. Given the more severe symptomatology, unfavorable course and impaired functioning, patients with an anxiety disorder and comorbid anxiety and depressive symptoms should receive prompt and adequate treatment.

Role of funding source

The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-MW, grant number 10-000-1002). ZonMW had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Conflict of interest

All authors declare that they have no conflicts of interest.

Acknowledgments

The infrastructure for the NESDA study is supported by participating universities and mental health care organizations (VU University Medical Center, GGZinGeest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, ...
References


